News

Enlarge image

PoliticsEU

New president fires against EU

25.06.2013 - Sanofi’s CEO Christopher Viehbacher has been elected head of Europe’s pharma lobby organisation EFPIA. He started off with threatening EU politicians.

Christopher A. Viehbacher, Chief Executive Officer of Sanofi, was elected President of EFPIA, the European Federation of Pharmaceutical Industries and Associations, for a 2-year term. Viehbacher, holding both German and Canadian nationalities, took the chance after the election on June 24 to take up a stance on EU politics. The quarrel is about the European Medicine Agency’s (EMA) strategy to make drug development more transparent by disclosing data from clinical studies. The EMA hopes that the released data on already approved drugs could spur research in general. The industry, however, believes competitors from the biologics field may gain valuable information and thus feels bullied. Speaking of his very own Sanofi, Viehbacher argues in a Reuters release: „If I was to say where would I put the next euro of investment, I would say either the next euro of investment would go to the United States or to emerging markets.“ The data in question also includes information that may help competitors in the field, Viehbacher fears that other companies like GSK or Roche got less exercised on the issue. They plan to open the corresponding raw data files for qualified researchers.

Beyond that discussion, Viehbacher also identified other construction sites, The EFPIA head urged: „Given the chronic deficits of healthcare systems, we must work differently, build collaborative policies and combine our strengths at both national and European levels. As we want Healthcare to be a growth engine for Europe, our industry must focus on three priorities: patient access, science & innovation and competitiveness.” Viehbacher follows Andrew Witty from UK’s GlaxoSmithKline. Joining him at the head of the EFPIA board will be two newly elected Vice Presidents, Roch Doliveux, Chief Executive Officer of UCB, and Joseph Jimenez, Chief Executive Officer of Novartis.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/new-president-fires-against-eu.html

R&DUKIreland

12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PAION (D)1.77 EUR63.89%
  • 4SC (D)2.95 EUR11.32%
  • BIONOR PHARMA (N)0.86 NOK8.86%

FLOP

  • STENTYS (F)2.83 EUR-26.30%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • KARO BIO (S)24.60 SEK-16.04%

TOP

  • VERONA PHARMA (UK)3.40 GBP23.6%
  • IXICO (UK)35.75 GBP21.2%
  • SERODUS (N)2.71 NOK15.8%

FLOP

  • STENTYS (F)2.83 EUR-49.0%
  • BIONOR PHARMA (N)0.86 NOK-46.2%
  • MOLMED (I)0.24 EUR-35.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.60 SEK3053.8%
  • 4SC (D)2.95 EUR243.0%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-86.0%
  • BIOTEST (D)13.79 EUR-85.3%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 12.02.2016